IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

PubWeight™: 1.42^‹?› | Rank: Top 5%

🔗 View Article (PMID 27720136)

Published in Lancet Oncol on October 03, 2016

Authors

Brian I Rini¹, Arnulf Stenzl², Romauld Zdrojowy³, Mikhail Kogan⁴, Mikhail Shkolnik⁵, Stephane Oudard⁶, Steffen Weikert⁷, Sergio Bracarda⁸, Simon J Crabb⁹, Jens Bedke², Joerg Ludwig¹⁰, Dominik Maurer¹⁰, Regina Mendrzyk¹⁰, Claudia Wagner¹⁰, Andrea Mahr¹⁰, Jens Fritsche¹⁰, Toni Weinschenk¹⁰, Steffen Walter¹⁰, Alexandra Kirner¹⁰, Harpreet Singh-Jasuja¹⁰, Carsten Reinhardt¹⁰, Tim Eisen¹¹

Author Affiliations

1: Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA. Electronic address: rinib2@ccf.org.
2: University of Tübingen, Tübingen, Germany.
3: Wroclaw Medical University, Wroclaw, Poland.
4: Rostov State Medical University of Roszdrav, Rostov-on-Don, Russia.
5: Russian Scientific Center of Radiology and Surgery Technologies, St Petersburg, Russia.
6: Hopital Europeen Georges Pompidou, Paris, France.
7: Vivantes Humboldt Clinic, Berlin, Germany.
8: Ospedale San Donato, Arezzo, Italy.
9: University of Southampton, Southampton, UK.
10: Immatics Biotechnologies, Tübingen, Germany.
11: University of Cambridge, Cambridge, UK.

Associated clinical trials:

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | NCT01265901

Articles citing this ↘

Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat Rev Urol (2017) 0.77

Interference of retroviral envelope with vaccine-induced CD8(+) T cell responses is relieved by co-administration of cytokine-encoding vectors. Retrovirology (2017) 0.75

Kidney cancer: IMPRINT: no survival benefit of IMA901 in RCC. Nat Rev Nephrol (2016) 0.75

Articles by these authors ⇆

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol (2016) 2.30

Pros-IT CNR: an Italian prostate cancer monitoring project. Aging Clin Exp Res (2017) 0.75

Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunol Rev (2017) 0.75

Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group. Eur Urol (2016) 0.75

Corrigendum re: "Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group" [Eur Urol 2017;71:723-6]. Eur Urol (2017) 0.75

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncol (2017) 0.75

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol (2016) 0.75